Pieris Pharmaceuticals announced the appointment of a new senior vice president and chief financial officer.
Pieris Pharmaceuticals (NASDAQ:PIRS) announced the appointment of a new senior vice president and chief financial officer.
As quoted in the press release:
Dr. Allan Reine is an accomplished healthcare investor and brings to Pieris a wealth of capital markets experience, a deep biotech background, and a strong scientific acumen.
“It’s a pleasure to welcome Allan to the Pieris team at this exciting phase,” commented Stephen Yoder, President and CEO. “His medical background, industry network, and successful track record as a growth-focused healthcare investor bring unprecedented strategic value to the Company from a corporate finance perspective.”
Prior to joining Pieris, from 2012 through August 2017, Dr. Reine was a portfolio manager at Lombard Odier Asset Management, where he ran a healthcare portfolio focused on biotechnology and pharmaceutical companies. Before joining Lombard Odier, Dr. Reine served as a healthcare portfolio manager at various funds, from 2003 through 2012 including Citi Principal Strategies, SAC Capital, Trivium Capital and Alexandra Investment Management. Dr. Reine began his career in 2001 at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research. Dr. Reine received his M.D. from the University of Toronto, and his Bachelor of Science in Statistical Sciences from the University of Western Ontario.